GH Research (GHRS) Stock Price, News & Analysis

Company Overview

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression. An additional preclinical candidate, GH002, is being developed for broader indications including anxiety, cognitive impairment and substance use disorders. GH Research employs a proprietary platform to optimize dosing, formulation delivery and real-time patient monitoring.

Founded in 2017 by biotechnology entrepreneur Christian Angermayer, GH Research operates research facilities in Ireland and maintains collaborations with academic institutions and contract research organizations across Europe and North America. The executive leadership team combines expertise in psychiatry, neuroscience and drug development to advance the company’s pipeline.

GH Research engages with regulatory authorities in multiple jurisdictions as it plans to initiate later-stage clinical trials and pursue strategic partnerships. The company’s goal is to bring innovative, psychedelic-derived therapeutics to patients worldwide who face debilitating psychiatric conditions.

Key Stats

• Today's Range: $20.87 to $22.36
• 50-Day Range: $13.03 to $22.44
• 52-Week Range: $10.66 to $24.66
• Volume: 35,496 shs
• Average Volume: 316,665 shs
• Market Capitalization: $1.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.00
• Consensus Rating: Moderate Buy

GH Research Stock Analysis - MarketRank™

GH Research scored higher than 63% of companies evaluated by MarketBeat, and ranked 173rd out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GH Research has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

GH Research has a consensus price target of $40.13, representing about 80.7% upside from its current price of $22.21.

Amount of Analyst Coverage

GH Research has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GH Research are expected to decrease in the coming year, from ($1.52) to ($2.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GH Research is -27.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GH Research is -27.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GH Research has a P/B Ratio of 4.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.46% of the float of GH Research has been sold short.

Short Interest Ratio / Days to Cover

GH Research has a short interest ratio ("days to cover") of 5.85.

Change versus previous month

Short interest in GH Research has recently decreased by 0.20%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GH Research does not currently pay a dividend.

Dividend Growth

GH Research does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.11

News Sentiment

GH Research has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for GH Research this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for GHRS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

5 people have added GH Research to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GH Research insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 5/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GHRS
• CIK: 1855129
• Web: www.ghres.com
• Phone: 212-450-4000
• Fax: N/A
• Employees: 10
• Year Founded: 2018

Price Target and Rating

• Average Price Target for GH Research: $41.00
• High Price Target: $70.00
• Low Price Target: $32.00
• Potential Upside/Downside: +93.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -16.30%
• Return on Assets: -15.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 34.13
• Quick Ratio: 34.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.51 per share
• Price / Book: 4.70

Miscellaneous

• Outstanding Shares: 62,029,000
• Free Float: 36,225,000
• Market Cap: $1.31 billion
• Optionable: Optionable
• Beta: 1.27